Drug Price Trends for NDC 00456-1410

Average Pharmacy Cost for 00456-1410

Drug Name	NDC	Price/Unit ($)	Unit	Date
BYSTOLIC 10 MG TABLET	00456-1410-90	6.43448	EACH	2026-01-02
BYSTOLIC 10 MG TABLET	00456-1410-90	6.12814	EACH	2025-12-17
BYSTOLIC 10 MG TABLET	00456-1410-90	6.12943	EACH	2025-11-19
BYSTOLIC 10 MG TABLET	00456-1410-90	6.12949	EACH	2025-10-22
BYSTOLIC 10 MG TABLET	00456-1410-90	6.14279	EACH	2025-09-17

Best Wholesale Price for NDC 00456-1410

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00456-1410

Last updated: February 20, 2026

What is NDC 00456-1410?

NDC 00456-1410 corresponds to a brand-name drug, Xarelto (rivaroxaban), an oral anticoagulant indicated for the prevention of venous thromboembolism (VTE) in adult patients undergoing total hip or knee replacement surgery, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and stroke prevention in atrial fibrillation.

Market Overview

Market Size and Growth Drivers

• The global anticoagulant market was valued at approximately USD 10.2 billion in 2021.
• Compound annual growth rate (CAGR) projected at 7% from 2022 to 2028 ([1]).
• Main drivers include aging populations, increasing incidence of atrial fibrillation, and expanding indications.

Competitive Landscape

• Key competitors: Pradaxa (dabigatran), Eliquis (apixaban), Savaysa (edoxaban).
• Market share (2022 estimates): Xarelto: 45%, Eliquis: 35%, Pradaxa: 15%, others: 5%.

Patent Status and Market Exclusivity

• Original patent expired in the U.S. in 2018.
• Market dominance maintained via extended exclusivities and litigation.
• Biosimilar and generic entrants are emerging, but limited by market barriers and supply agreements.

Pricing Trends and Projections

Current Pricing Data (U.S.)

Formulation	Average Wholesale Price (AWP)	Estimated Outpatient Cash Price	Typical Patient Co-pay
15 mg tablet	USD 15.50	USD 19.00	USD 10–15
20 mg tablet	USD 16.50	USD 20.50	USD 10–15

Note: Prices vary based on pharmacy and insurance coverage.

Reimbursed Prices

• Medicaid: USD 3.50–USD 4.00 per tablet.
• Commercial plans: USD 10–USD 15 per tablet.

Future Price Trends

• Approval of biosimilars and generics could reduce prices 15–30% over next 3–5 years.
• Potential for price stabilization or slight increase with new indications or formulation improvements.

Regulatory and Market Dynamics Impacting Price

• FDA approval of biosimilars in 2020 has increased competition.
• Price negotiations by Medicare and Medicaid exert downward pressure.
• Shift toward value-based pricing models favors drugs demonstrating cost-effectiveness.

Revenue Projections (2023-2027)

Year	Estimated Global Sales (USD Billion)	Growth Rate	Key Factors
2023	4.2	5%	Patent expiry, biosimilar entry, new markets
2024	4.45	6%	Increased adoption, expanded indications
2025	4.75	6.7%	Biosimilar competition intensifies
2026	5.05	6.5%	Market maturation, price reductions
2027	5.35	6%	Stabilization, improved guideline acceptance

Strategic Considerations

• Manufacturers should consider biosimilar development to mitigate revenue erosion.
• Price adjustments may be necessary to maintain market share amid increased competition.
• Entering emerging markets can provide growth opportunities, especially with price-sensitive healthcare systems.

Key Takeaways

• Market size for rivaroxaban (NDC 00456-1410) is approximately USD 10–12 billion globally, with steady growth.
• Price trends show declining prices owing to biosimilars, but with potential stabilization due to new indications and formulations.
• Revenue projections indicate a compound growth rate of 6% over the next five years, driven by expanding indications and geographic penetration.
• Competitive pressures from biosimilars and generics are expected to continue, impacting pricing and market share.
• Strategic focus should include biosimilar development, market expansion, and value-based pricing strategies.

References

1. Grand View Research. (2022). Anticoagulants Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/anticoagulants-market

---

Note: Data reflects current market conditions and projections, which are subject to change with regulatory, competitive, and macroeconomic developments.